The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Burrows Scott L since 2021.
This trader's CIK number is 1853327.
At the time of last reporting, Burrows Scott L was the Chief Financial Officer of Spyre Therapeutics, Inc.. (stock ticker symbol SYRE).
Also see all insider trading activities at Spyre Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | SYRE | 0 | $0 | 18,428 | $299,639 | 0 | $0 |
| 2024 | SYRE | 0 | $0 | 18,531 | $522,073 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | ARQT | 0 | $0 | 2,141 | $34,352 | 0 | $0 |
| 2022 | ARQT | 0 | $0 | 723 | $12,559 | 5,000 | $8,405 |
| 2021 | ARQT | 0 | $0 | 12,560 | $252,142 | 0 | $0 |
1. Spyre Therapeutics, Inc. (SYRE)
2. Arcutis Biotherapeutics, Inc. (ARQT)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | SYRE | Sale | 18,428 | 16.26 | 299,639 |
| 2024-09-03 | SYRE | Sale | 18,531 | 28.17 | 522,073 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-03-06 | ARQT | Sale | 291 | 15.26 | 4,441 |
| 2023-02-28 | ARQT | Sale | 416 | 16.17 | 6,725 |
| 2023-03-02 | ARQT | Sale | 1,434 | 16.17 | 23,186 |
| 2022-09-16 | ARQT | Option Ex | 5,000 | 1.68 | 8,405 |
| 2022-03-04 | ARQT | Sale | 293 | 16.86 | 4,939 |
| 2022-03-07 | ARQT | Sale | 10 | 16.45 | 164 |
| 2022-03-01 | ARQT | Sale | 420 | 17.75 | 7,456 |
| 2021-12-27 | ARQT | Sale | 12,560 | 20.07 | 252,142 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Burrows Scott L (Chief Financial Officer of Spyre Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.